Amylyx Pharmaceuticals is facing a new hurdle — a second round of questions from a European Medicines Agency (EMA) committee — in its quest to have AMX0035 approved as a treatment for amyotrophic lateral sclerosis (ALS) in Europe. The questions, from the Committee for Medicinal Products for…
European approval of AMX0035 for ALS faces new hurdle in review
On a snowy morning three years ago, in Ann Arbor, Michigan, my late husband, Jeff, sped the entire length of the University of Michigan football field in his blue power wheelchair. Light snow was falling as his brothers and I watched him fly down the field, a…
Anew Medical‘s targeted gene therapy candidate, ANEW-202, eased multiple mechanisms associated with amyotrophic lateral sclerosis (ALS), leading to improved muscle function and survival in a mouse model of the disease. The gene therapy, licensed on an exclusive worldwide basis from the Autonomous University of Barcelona, in Spain, is…
My husband, Todd, and I enjoy watching chickadees flit from a feeder that hangs from a mountain ash tree behind our house to one of the branches, where they crack the shells and eat the sunflower seeds. “Let Comet out,” Todd told me one morning. “There’s a squirrel in the…
QurAlis has secured $88 million to advance the clinical development of QRL-101 and QRL-201, its lead candidates for amyotrophic lateral sclerosis (ALS). The new series B financing, a second round of funding after the company met certain research milestones, brings the total investment to $143.5 million. The proceeds will…
Radicava ORS, an oral formulation of Radicava (edaravone), is now available to U.S. veterans living with amyotrophic lateral sclerosis (ALS), the therapy’s developer, Mitsubishi Tanabe Pharma America (MTPA), announced. The therapy was added to the U.S. Department of Veterans Affairs National Formulary (VANF) in June 2022, shortly after its…
The Muscular Dystrophy Association (MDA) is hosting its 16th annual MDA Atlanta Night of Hope Gala: A Benefit for ALS Research to raise funds for amyotrophic lateral sclerosis (ALS) research and care. The event will be held 6-11 p.m. EDT March 25 at the InterContinental Buckhead Atlanta. It…
Renowned neurologist and amyotrophic lateral sclerosis (ALS) investigator Merit Cudkowicz, MD, of Massachusetts General Hospital has been named this year’s recipient of the Muscular Dystrophy Association (MDA) Legacy Award for Achievement in Clinical Research. The award, which recognizes outstanding accomplishments in neuromuscular research, will be presented March 20…
Treatment with CNM-Au8 significantly delayed clinical worsening in people with amyotrophic lateral sclerosis (ALS), according to new exploratory analyses from the therapy’s arm of the HEALEY ALS platform trial. The experimental therapy, from Clene Nanomedicine, had previously been found to reduce the risk of death by more…
On the ski trail the other afternoon, I was feeling discouraged. I hadn’t slept well the previous couple of nights and had a low-grade headache, but I willed myself to keep going. Exercise is good for my body, and being in nature usually soothes my mind. They’re two of…
Recent Posts
- A dream takes me back to a time before life with ALS
- ALS ONE joining ALS Network to strengthen research, services
- Rollator revamp needed because design matters for living well with ALS
- Study probes high ALS risk in elite athletes and other ‘champions’
- First ALS patient dosed in study of experimental gene therapy VTx-002